Date: 2018-03-27
Type of information: Series A financing round
Company: Poietis (France)
Investors: WiSEED (France) Nouvelle Aquitaine Coinvestment Fund (France)
Amount: €5 million
Funding type: series A financing round, grant
Planned used:
- Poietis will use these funds to accelerate technological developments aimed at making its technology compatible with regulatory requirements and the Good Manufacturing Practices (GMP) for advanced therapy medicinal products (ATMPs). The goal will be to ensure the reproducibility, standardization and traceability of the tissue manufacturing process while ensuring the biological safety of bioprinted tissues. Consequently, bioprinted tissues could be implanted into patients from 2021. Poietis expectation is to consolidate its leadership and to take a significant part of the 3D bioprinting market, estimated at nearly 800 million in 2022 and 2.5 billion in 2024.
Others:
- • On March 27th 2018, Poietis announced the closing of a second round of financing. This €5m Series A round is mainly done through a new crowdfunding fund-raising on WiSEED platform, investment by the Nouvelle Aquitaine Co-investment Fund as well as the granting of non-dilutive funding obtained in the framework of the Phase 2 of the worldwide Innovation Challenge ("personalized medicine" call). In this fundraising, Poietis was supported by the firm McDermott, Will & Emery.
Therapeutic area: Technology - Services
Is general: Yes
